Publications by authors named "Anett Schwarze"
Clin Dev Immunol
August 2014
Article Synopsis
- TLR3 agonists, like RGC100, are promising for vaccines against tumors and pathogens due to their ability to activate dendritic cells and enhance T-cell responses.
- RGC100 has a defined chemical structure and good solubility, distinguishing it from the less predictable and more toxic poly(I:C).
- This novel agonist effectively stimulates myeloid dendritic cells to produce proinflammatory cytokines and boosts T-cell proliferation, making it a potential adjuvant for vaccination approaches.
